Hjem › Multipelt myelom › Rhode Island
Multipelt myelom kliniske forsøg i Rhode Island
6 studier for Multipelt myelom søger deltagere på steder i Rhode Island.
Byer i Rhode Island
Officiel studietekst (engelsk)
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Rhode Island Hospital, Providence
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05552222MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Rodhe Island Hospital, Providence
- The Miriam Hospital, Providence
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 24. aug. 2026 · NCT06152575Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- Smilow Cancer Hospital Care Center - Westerly, Westerly
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 19. aug. 2026 · NCT04566328Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
- Smilow Cancer Hospital Care Center - Westerly, Westerly
RekruttererFase 3
Alle aldre · Alle køn · Opdateret 10. jun. 2026 · NCT05561387A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Providence
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 22. apr. 2026 · NCT06679101IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- Rhode Island Hospital, Providence
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 3. jun. 2025 · NCT06119685Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.